

AD\_\_\_\_\_

Award Number: W81XWH-04-1-0322

TITLE: A Controlled Trial of Chemoprevention Using COX-2  
Inhibitors in an Avian Model of Spontaneous Ovarian  
Carcinogenesis

PRINCIPAL INVESTIGATOR: Mack N. Barnes, M.D.  
Wallace D. Berry, Ph.D.

CONTRACTING ORGANIZATION: University of Alabama at Birmingham  
Birmingham, Alabama 35294-0111

REPORT DATE: March 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050727 094

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                 |                                                                |                                                                               |                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------|
| <b>1. AGENCY USE ONLY</b><br>(Leave blank)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                 | <b>2. REPORT DATE</b><br>March 2005                            | <b>3. REPORT TYPE AND DATES COVERED</b><br>Annual (15 Feb 2004 - 15 Feb 2005) |                                 |
| <b>4. TITLE AND SUBTITLE</b><br>A Controlled Trial of Chemoprevention Using COX-2 Inhibitors in an Avian Model of Spontaneous Ovarian Carcinogenesis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                 |                                                                | <b>5. FUNDING NUMBERS</b><br>W81XWH-04-1-0322                                 |                                 |
| <b>6. AUTHOR(S)</b><br>Mack N. Barnes, M.D.<br>Wallace D. Berry, Ph.D.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                 |                                                                |                                                                               |                                 |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b><br>University of Alabama at Birmingham<br>Birmingham, Alabama 35294-0111<br><br>E-Mail: mbarnes@uabmc.edu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                 |                                                                | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>                               |                                 |
| <b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |                                                                | <b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>                       |                                 |
| <b>11. SUPPLEMENTARY NOTES</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                 |                                                                |                                                                               |                                 |
| <b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b><br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |                                                                |                                                                               | <b>12b. DISTRIBUTION CODE</b>   |
| <b>13. ABSTRACT (Maximum 200 Words)</b><br>While a strong rationale for chemoprevention of ovarian carcinoma exists, a mechanism for the comprehensive evaluation of novel compounds is severely impeded by the lack of a validated animal model of spontaneous ovarian carcinogenesis. At present, there is no verified, established model for this disease. In rodents, this type of cancer does not spontaneously develop. While studies investigating "induced" carcinomas have been performed they are hindered by biologic differences in induced and spontaneous tumor formation. Identification of spontaneous ovarian carcinogenesis in the laying hen ( <i>Gallus Domesticus</i> ) may provide the answer to this dilemma. Multiple reports have demonstrated a 30-50% rate of spontaneously arising genital tract adenocarcinomas in hens of 3-6 years of age. Thus, the purpose of this study will be to utilize this animal model to evaluate the ability of a COX-2 inhibitor to reduce the incidence of spontaneous ovarian carcinogenesis in this animal model. More importantly, identification of promising agents in surrogate animal models that simulate a high risk population would significantly impact the strategy of cancer chemoprevention for ovarian carcinoma and lead to subsequent endeavors in this neglected area of study. |                                                                 |                                                                |                                                                               |                                 |
| <b>14. SUBJECT TERMS</b><br>Ovarian neoplasms, chemoprevention, COX-2 inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                 |                                                                |                                                                               | <b>15. NUMBER OF PAGES</b><br>7 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                 |                                                                |                                                                               | <b>16. PRICE CODE</b>           |
| <b>17. SECURITY CLASSIFICATION OF REPORT</b><br>Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <b>18. SECURITY CLASSIFICATION OF THIS PAGE</b><br>Unclassified | <b>19. SECURITY CLASSIFICATION OF ABSTRACT</b><br>Unclassified | <b>20. LIMITATION OF ABSTRACT</b><br>Unlimited                                |                                 |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## Table of Contents

|                                   |     |
|-----------------------------------|-----|
| Cover.....                        | 1   |
| SF 298.....                       | 2   |
| Table of Contents .....           | 3   |
| Introduction.....                 | 4   |
| Body.....                         | 4-6 |
| Key Research Accomplishments..... | 6   |
| Reportable Outcomes.....          | 6   |
| Conclusions.....                  | 6   |
| References.....                   | 6-7 |

**ANNUAL REPORT: CONTROLLED TRIAL OF CHEMOPREVENTION USING COX-2 INHIBITORS IN AN AVIAN MODEL OF SPONTANEOUS OVARIAN CARCINOGENESIS (W81XWH-04-1-0322)**

**INVESTIGATORS:** Mack N. Barnes MD, Wallace D. Berry PhD

**INTRODUCTION**

Ovarian carcinoma represents the fourth leading cause of cancer death in the female population and is the most fatal gynecologic malignancy. Secondary to its presentation as advanced disease in the majority of cases and its low prevalence, strategies that center on therapeutics or screening are unlikely to impact the overall death rate. Therefore, when considering strategies to decrease the deaths attributable to ovarian carcinoma, prevention of disease represents the most rational approach. This model of intervention is consistent with statements from the National Cancer Institute which have identified a need for development of chemoprevention strategies in ovarian carcinoma. Additional support of ovarian cancer chemoprevention is the historical benefit of oral contraceptives and retinoic acid derivatives. A critical component of developing chemopreventive strategies in ovarian carcinoma is identification of promising new compounds in validated animal models of spontaneous ovarian carcinogenesis. As will be detailed subsequently, a novel avian model utilizes the laying hen (*Gallus Domesticus*) and exploits the high rate of spontaneous ovarian carcinogenesis observed in this avian species. **Therefore, our hypothesis is that administration of a COX-2 inhibitor will result in a decreased rate of development of ovarian carcinoma in an avian model of spontaneous ovarian carcinogenesis.** The specific aims and methods pursuant to this proposal are as follows: Specific Aim#1: Determine the maximally tolerated dose (mg/kg) of COX-2 inhibitor, admixed with standard feed, in the laying hen. The effect of varying doses of COX-2 inhibitor on egg-laying activity as a surrogate marker for ovulatory frequency will also be assessed. The maximally tolerated dose will then be used in the controlled trial. Specific Aim#2: Determine, in a controlled chemoprevention trial, the ability of a COX-2 inhibitor to inhibit the development of spontaneously arising genital tract adenocarcinoma in the laying hen. These studies will address an important and underdeveloped investigational endeavor in women's health. Clearly, chemoprevention represents the most rational investigational strategy to achieve a meaningful reduction in deaths from ovarian carcinoma. More importantly, identification of promising agents in surrogate animal models that simulate a high risk population would significantly impact the strategy of cancer chemoprevention for ovarian carcinoma and lead to subsequent endeavors in this neglected area of study. As detailed subsequently, and in accordance with the timeline proposed in the original statement of work, the hens were acquired, the dose finding and toxicity study completed and the controlled trial initiated.

**BODY**

As noted above the statement of work included 2 specific aims: Specific Aim#1: Determine the maximally tolerated dose (mg/kg) of COX-2 inhibitor, admixed with

standard feed, in the laying hen. The effect of varying doses of COX-2 inhibitor on egg-laying activity as a surrogate marker for ovulatory frequency will also be assessed. The maximally tolerated dose will then be used in the controlled trial. Specific Aim#2: Determine, in a controlled chemoprevention trial, the ability of a COX-2 inhibitor to inhibit the development of spontaneously arising genital tract adenocarcinoma in the laying hen. The accomplishments toward the successful completion of each specific aim will be addressed individually.

Specific Aim#1: Determine the maximally tolerated dose (mg/kg) of COX-2 inhibitor, admixed with standard feed, in the laying hen. The effect of varying doses of COX-2 inhibitor on egg-laying activity as a surrogate marker for ovulatory frequency will also be assessed. The maximally tolerated dose will then be used in the controlled trial.

There is a paucity of information regarding the use of COX-2 inhibitors in the avian hen. Rimadyl (Pharmacia Inc.) is a COX-2 specific inhibitor approved for use in veterinary medicine and available in a stable powder form. Therefore, in accordance with specific aim #1 a dose/toxicity study was performed prior to initiation of the larger study. This study was carried out in accordance with plans outlined in the original proposal.

Three dose levels were established as follows:

- Control: 0 mg/kg body weight
- Dose 1: 2.5 mg/kg body weight
- Dose 2: 5 mg/kg body weight
- Dose 3: 10 mg/kg body weight

Rimadyl was added with other feed ingredients at the time feed was mixed in the feed mill and delivered to the hens. 5 hens were utilized per dose level for a total of 20 hens. The hens were monitored for egg laying activity as defined by percent egg laying activity control (0 mg/kg) and egg shell quality. In addition, toxicity will be monitored based on general appearance, feather quality, evidence of gastrointestinal bleeding, and death. Over an 8 week study period, no toxicity and no lethal events were noted. In addition, there did not appear to be any effect on ovulatory activity, even at the highest dose level. Given, the ability of these hens to tolerate the highest dose level, 10mg/kg body weight was determined to be the dose we would utilize in the controlled trial.

Specific Aim#2: Determine, in a controlled chemoprevention trial, the ability of a COX-2 inhibitor to inhibit the development of spontaneously arising genital tract adenocarcinoma in the laying hen.

As outlined in the proposal, a power calculation had been performed using assuming a 40% incidence of genital tract adenocarcinoma. It was estimated that to identify a reduction in disease of 20% at the 0.05 level of significance a treatment group of 88 hens and a control group of 88 hens would be required. The informative cases defined as those hens completing the course of treatment (as previously used in a published study. Significant attrition from non-malignant causes is known to occur as hens age. Therefore, to initiate this study 480 hens (*Gallus Domesticus*) were acquired 8/3/04.

This allowed the establishment of a treatment group (240 hens) and a control group (240 hens) that should account for attrition. It is our practice to allow a period of time for hens to "acclimate" and, therefore, a period of 8 weeks was utilized to allow the hens to acclimate. The controlled study was then initiated October 1, 2004 using a daily dose of Rimadyl of 10mg/kg body weight. This trial is ongoing at the date of this report and planned for 48 months.

## **KEY RESEARCH ACCOMPLISHMENTS**

- Dose Finding Study completed
- No toxicity demonstrated for Rimadyl (COX-2 inhibitor) at 10mg/kg body weight
- Hens acquired for trial and acclimated
- Controlled trial initiated 10/04

## **REPORTABLE OUTCOMES.**

Too early.

## **CONCLUSIONS**

Too early.

## **REFERENCES (From Proposal)**

1. Partridge E, Barnes M. Epithelial ovarian cancer: Prevention, diagnosis and treatment. *CA-A Cancer Journal for Clinicians* 49(5): 297-320, 1999.
2. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer; Screening, treatment and follow-up. *JAMA* 273: 491-7, 1995.
3. Singh-Ranger G, Mokbel K. The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. *Eur J of Surgical Oncology*. 28; 729-737, 2002.
4. Rioux N, Castonguay A. Prevention of NK induced lung tumorigenesis in A/J mice by acetylsalicylic and NS398. *Cancer Res* 58; 5354-5360, 1998.
5. Ogino M, Minoura S. Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents. *Int J of Clinical Oncology* 6; 84-89, 2001.
6. Sawakoa H, Kawano S, Tsujii M, Murata H, Hori M. Effects of NSAIDs on proliferation of gastric cancer in vitro: possible implication of cyclooxygenase-2 in cancer development. *J Clinical Gastroenterology*. 27 suppl.; s47-s52, 1998.
7. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. *Cancer Res* 54; 5602-5606, 1994
8. Rodriguez-Burford C, Barnes MN, Oelschlager DK, et al. Effects of non-steroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: Preclinical evaluation of NSAIDs as chemopreventive agents. *Clin Cancer Res* 8:202-209, 2002.

9. Barnes M, Grizzle W, Grubbs C, Partridge E. Paradigms for primary prevention of ovarian carcinoma. *CA Cancer J Clin* 52:216-225, 2002
10. Murdoch WJ, Lund SA. Prostaglandin-independent anovulatory mechanism of indomethacin action: Inhibition of tumor necrosis factor alpha-induced sheep ovarian cell apoptosis. *Biol Reprod* 61:1655-1659, 1999.
11. Lim H, Paria B, Das S, Dinchuk J, Langenbach R, Trzaskos J, Dey S. Multiple female reproductive failures in cyclooxygenase 2 deficient mice. *Cell* 91: 197-208, 1997.
12. Killick S, Elstein M. Pharmacologic production of lutenized follicles by prostaglandin synthetase inhibitors. *Fertility and Steril* 47: 773-777, 1987
13. Espey LL, Kohda H, Mori T, et al. Rat ovarian prostaglandin levels and ovulation as indicators of the strength of non-steroidal anti-inflammatory drugs. *Prostaglandins* 36:875-879, 1988.
14. Ando M, Kol S, Irahara M, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) block the late, prostanoid-dependent/ceramide-independent component of ovarian IL1 action: Implications for the ovulatory process. *Mol Cell Endocrinol* 157:21-30, 1999.
15. Connolly D, Bao R, Nikitin A, et al. Female mice chimeric for expression of the simian virus 40 Tag under control of the MISIR promoter develop epithelial ovarian cancer. *Cancer Res* 63: 1389-1397, 2003.
16. Orsulic S, Li Y, Soslow R, et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. *Cancer Cells* 1: 53-62, 2002.
17. Fredrickson T. Ovarian tumors of the hen. *Env Health Perspectives* 73: 35-51, 1987.
18. Burford C, Barnes M, Berry W, Partridge E, Grizzle W. Immunohistochemical expression of molecular markers in an avian model: A potential model for preclinical evaluation of agents for ovarian cancer chemoprevention. *Gynecol Oncol* 81: 373-379, 2001.
19. Barnes M, Berry W, Straughn M, Kirby T, Leath C, Huh W, Grizzle W, Partridge E. A controlled trial of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. *Gynecol Oncol* 87, 57-63, 2002
20. Wenham R, Lancaster J, Berchuck A, et al. Molecular characterization of avian ovarian cancer (Abst). *Gynecol Oncol* 88: 255, 2003.
21. Rodriguez G, Walmer D, Cline M, Krigman H, Lessey B, Whitaker R, Dodge R, Hughes C. Effect of Progestin on the ovarian epithelium of macaques: Cancer prevention through apoptosis. *J Soc Gynecol Invest* 5: 271-6, 1998.